Ergolin
Izgled
(IUPAC) ime | |||
---|---|---|---|
(6aR)-4,6,6a,7,8,9,10,10a-oktahidroindolo [4,3-fg] hinolin | |||
Klinički podaci | |||
Identifikatori | |||
CAS broj | 478-88-6 | ||
ATC kod | nije dodeljen | ||
PubChem[1][2] | 6857537 | ||
ChemSpider[3] | 5256873 | ||
ChEBI | CHEBI:38484 | ||
Hemijski podaci | |||
Formula | C14H16N2 | ||
Mol. masa | 212,29 g/mol | ||
SMILES | eMolekuli & PubHem | ||
| |||
Farmakoinformacioni podaci | |||
Trudnoća | ? | ||
Pravni status |
Ergolin je hemijsko jedinjenje čija strukturna osnova je prisutna u raznovrsnom nizu alkaloida, među kojima su psihodelični lekovi (npr. lizerginska kiselina i LSD).[4] Derivati ergolina nalaze kliničku primenu kao vazokonstriktori (agonisti 5-HT1 receptora—ergotamin[5]) i u lečenju migrene (zajedno sa kofeinom) i Parkinsonove bolesti. Neki ergolinski alkaloidi su nađeni u ergot gljivama i smatra se da su jedan od uzroka ergotizma[6], koje uzrokuje konvulzivne i gangrenozne simptome.
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.
- ↑ Schardl CL, Panaccione DG, Tudzynski P (2006). „Ergot alkaloids – biology and molecular biology”. The Alkaloids: Chemistry and Biology. The Alkaloids: Chemistry and Biology 63: 45-86. DOI:10.1016/S1099-4831(06)63002-2. ISBN 9780124695634. PMID 17133714.
- ↑ Sanders SW, Haering N, Mosberg H, Jaeger H. Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing. Eur J Clin Pharmacol 1983; 30: 331–4.
- ↑ Piquemal, R et al (June 1998). „Successful treatment of ergotism with Iloprost--a case report.”. Angiology 49 (6): 493-497.